Photonews Logo Photonews logo
  • Home
  • Pakistan
    • Punjab
    • Sindh
    • Khyber Pakhtunkhwa
    • Azad Jammu Kashmir
    • Balochistan
    • Gilgit – Baltistan
  • World
  • Business
  • Entertainment
  • Videos
    Gen V Season 2 trailer
    Videos

    Gen V Season 2 Trailer Cast, Plot, Premiere Details

    July 26, 2025 3 Min Read
    IShowSpeed Daniel La Belle race
    Videos

    IShowSpeed Beats Daniel La Belle in 40-Meter Race, Hits 41M Subscribers

    June 24, 2025 2 Min Read
    Cardi B new single Outside
    Videos

    Cardi B’s ‘Outside’ Single Sparks Buzz Over Offset and Stefon Diggs

    June 20, 2025 2 Min Read
  • Sports
  • Technology
  • Offbeat
  • Blog
  • Contact
Reading: Sanofi Acquires Blueprint Medicines for $9.5B
PhotoNews Pakistan PhotoNews Pakistan
Font ResizerAa
Search
  • Home
  • Pakistan
    • Punjab
    • Sindh
    • Khyber Pakhtunkhwa
    • Balochistan
    • Azad Jammu Kashmir
    • Gilgit – Baltistan
  • World
  • Business
  • Entertainment
  • Videos
  • Sports
  • Technology
  • Offbeat
  • Blog
  • Contact
Have an existing account? Sign In
Follow US
© 2022 Photonews. All Rights Reserved.
Sanofi Acquires Blueprint Medicines
PhotoNews Pakistan > Business > Sanofi Acquires Blueprint Medicines for $9.5B
Business

Sanofi Acquires Blueprint Medicines for $9.5B

Web Desk
By Web Desk Published June 2, 2025 2 Min Read
Share
Photo Credit: ReBrand
SHARE

On June 2, 2025, French pharmaceutical giant Sanofi announced its acquisition of U.S.-based Blueprint Medicines for up to $9.5 billion, marking the largest European healthcare deal of the year.

The acquisition of Sanofi Blueprint Medicines will enhance Sanofi’s immunology and rare disease portfolio with Blueprint’s FDA-approved drug Ayvakit, as detailed in a press release on Sanofi’s website, reported by Reuters.

According to Bloomberg, Sanofi will purchase shares of Blueprint for $129 each in cash, reflecting a premium that has increased Blueprint’s stock price in premarket trading. Blueprint specialises in treating systemic mastocytosis, a rare blood disorder, and offers Ayvakit, the only approved therapy for its advanced form. The company also has a promising pipeline that includes elenestinib and BLU-808. CEO Paul Hudson described the acquisition as a “strategic leap” for Sanofi’s focus on immunology.

We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases.

— Sanofi (@sanofi) June 2, 2025

Strategic and Financial Impact

J.P. Morgan analysts project Ayvakit could generate $2 billion annually by 2030, strengthening Sanofi’s rare disease portfolio. The acquisition aligns with Sanofi’s R&D push, following deals for Vigil Neuroscience and Inhibrx, despite a recent lung disease drug trial setback. The move taps U.S. manufacturing incentives, positioning Sanofi as a global immunology leader.

Industry and Public Reactions

The addition of the Ayvakit systemic mastocytosis drug has been hailed as a game changer. Some investors expressed caution over its high valuation, but analysts see long-term growth, according to Livemint. The pharma deal for 2025 underscores Sanofi’s ambition to outpace its competitors.

Sanofi’s acquisition of Blueprint Medicines solidifies the company’s leadership in immunology and therapies for rare diseases, strengthening its competitive position worldwide. As the pharmaceutical landscape evolves in 2025, this deal underscores Sanofi’s strategic shift towards innovation and emphasises its commitment to addressing unmet medical needs.

TAGGED:Featured
Share This Article
Facebook Twitter Pinterest Whatsapp Whatsapp LinkedIn Email Copy Link Print
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Advertisement

HBL Saving Made Easy
HBL Saving Made Easy

Recent Posts

Pakistan Stock Exchange 2025

PSX Closes Higher Despite Mixed Session as SBP Holds Policy Rate Steady

Kamchatka earthquake impact on Moscow

Why Russia’s Sixth Strongest Earthquake Didn’t Impact Moscow

Meta AI coding interviews 2025

Meta Introduces AI-Enabled Coding Tests to Job Interviews

Post Archives

More Popular from Photonews

Pakistan vs India Asia Cup 2025
Sports

BCCI Confirms India-Pakistan Clash in Asia Cup 2025, Rejects Withdrawal Rumors

3 Min Read
Samsung Tesla AI chip deal
Business

Samsung Secures $16.5 Billion Deal to Produce Tesla AI Chips in Texas

3 Min Read
Fantastic Four First Steps
Entertainment

Fantastic Four First Steps July 2025: Cast, Plot, Rotten Tomatoes Score

3 Min Read
Top NewsWorld

An-24 Plane Crash in Russia Kills 48, Raises Concerns Over Soviet-Era Aircraft

On July 24, 2025, an Antonov An-24 passenger plane, carrying 48 people, crashed in Russia's Amur…

July 25, 2025
BusinessTop News

Donald Trump Announces 25% Tariff on Indian Imports Effective August 1

On Wednesday, former US President Donald Trump announced via his social media platform Truth Social that…

July 30, 2025
Sports

Al-Nassr Nears £44M Deal for Chelsea’s Joao Felix

Al-Nassr is nearing a £44 million agreement to sign Chelsea forward João Félix, with negotiations progressing…

July 27, 2025
Pakistan

ECP Announces By-Election Schedule for Four Vacant Seats After PTI Disqualifications

The ECP disqualified Senator Ejaz Chaudhry, Punjab Assembly Opposition Leader Malik Ahmad Bhachar, and MNA Ahmed…

July 30, 2025
PhotoNews Pakistan

Always Stay Up to Date

Subscribe to our newsletter to get our newest articles instantly!

Categories

  • World
  • Pakistan
  • Punjab
  • Sindh
  • Khyber Pakhtunkhwa
  • Balochistan
  • Azad Jammu Kashmir

 

  • Top News
  • Business
  • Entertainment
  • Sports
  • Videos
  • Tech
  • Offbeat
  • Blog

© 2024 Phototnews
All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?